News · 26 weeks34-17%
2025-12-142026-06-07
Mix2290d
- SEC Filings9(41%)
- Other7(32%)
- Earnings3(14%)
- Insider2(9%)
- M&A1(5%)
Latest news
25 items- PRVivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026LITTLETON, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA"), today announced that members of its executive management team will participate in The Small Cap Showcase & WTR Insights, taking place on June 9, 2026, in New York City. Representing the Company, Kirk Hunstman, CEO, will deliver a corporate presentation at 11:30 am ET and will participate in one-on-one meetings with pre-qualified investors throughout the day. The Small C
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq ListingLITTLETON, Colo., June 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA"), today announced that it has entered into a binding agreement with its senior, secured lender, Streeterville Capital, LLC (Streeterville) to exchange up to $4.5 million of its outstanding debt into a combination of perpetual, nonconvertible preferred stock and shares of common stock of the Company. In addition, the agreement includes commitments from Streeterville to susp
- SECSEC Form 10-Q filed by Vivos Therapeutics Inc.10-Q - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational UpdateYear-over-year revenue increased 70%, reflecting contribution from Vivos' acquisition of The Sleep Center of Nevada Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA"), today reported financial results and operating highlights for the first quarter ended March 31, 2026. Kirk Huntsman, Vivos' Chairman and Chief Executive Officer, stated "Our significant revenue increas
- SECSEC Form NT 10-Q filed by Vivos Therapeutics Inc.NT 10-Q - Vivos Therapeutics, Inc. (0001716166) (Filer)
- SECSEC Form SCHEDULE 13G filed by Vivos Therapeutics Inc.SCHEDULE 13G - Vivos Therapeutics, Inc. (0001716166) (Subject)
- SECSEC Form EFFECT filed by Vivos Therapeutics Inc.EFFECT - Vivos Therapeutics, Inc. (0001716166) (Filer)
- SECSEC Form 424B3 filed by Vivos Therapeutics Inc.424B3 - Vivos Therapeutics, Inc. (0001716166) (Filer)
- SECAmendment: SEC Form S-3/A filed by Vivos Therapeutics Inc.S-3/A - Vivos Therapeutics, Inc. (0001716166) (Filer)
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- SECSEC Form 10-K filed by Vivos Therapeutics Inc.10-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics Reports Full Year 2025 Financial ResultsFull Year 2025 revenue increased 16% Integration of The Sleep Center of Nevada and shift in business model support path to improved revenues, margins and cash flow Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA"), today reported financial results and operating highlights for the full year ended December 31, 2025. Full Year 2025 Financial and Operating Summary R
- PRVivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference CallLITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA"), announced it plans to release its full year 2025 financial results after market close today, Wednesday, April 15, 2026. The Company will conduct a conference call at 5:00 pm (Eastern Time) to review the results and provide operational updates. Vivos encourages investors and other interested parties to join its conference call today at 5:00 p.m. Eastern time. Management w
- INSIDERSEC Form 3 filed by new insider V-Co Investors 3 Llc3 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
- PRVivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca PartnersLITTLETON, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA"), announced that it has closed on a private placement with V-Co Investors 3 LLC ("V-Co 3"), an affiliate of New Seneca Partners Inc. ("Seneca"). Gross proceeds of $2.25 million including the conversion of a previously announced bridge note of $1.4 million (prior to giving effect to an associated original issue discount). The private placement closed on March 31, 2026. This
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- INSIDERSEC Form 4 filed by Skaff Michael C4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
- SECSEC Form NT 10-K filed by Vivos Therapeutics Inc.NT 10-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada MarketInsurance Coverage on Vivos Appliances and Treatment Now Available to a Significant Number of Nevada Patients Previously Unable to Access Coverage Concurrently, Vivos Implements Cost Reduction Initiatives Related to Legacy Business Model to Focus on Scaling its Medical Affiliation Distribution Model LITTLETON, Colo., March 26, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (OSA), today announced that physician-owned professional entities supported by t
- PRRecent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral AnatomyLITTLETON, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders and associated chronic health conditions, today announced that an a recent study published in the Journal of Clinical Medicine supports Vivos' long maintained belief that dental and facial morphology characterized by narrow palatal (upper) dental arches, high peaked palates, and recessed lower jaws were directly correlated to the prevalence and severity of obstructive sleep apnea (OSA) in adults and children. Over the past decade, Vivos-trained provider
- INSIDERNew insider Johnson Gregg C claimed ownership of 3,997 shares (SEC Form 3)3 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth's Groundbreaking FDA-Cleared Allergy and Sleep TechnologiesVivos adds more cutting-edge products to its roster serving the breathing and sleep wellness market LITTLETON, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders, and SoundHealth, a Silicon Valley based health technology company focused on AI enabled, clinically proven allergy and sleep therapeutics, today announced a collaboration to advance public awareness and access to SoundHealth's consumer-focused airway and sleep health technologies. The collaboration leverages Vivos' extensive national network of over 2,00
VVOS FAQ
7 questionsWhat does Vivos Therapeutics Inc. do?
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea (OSA). Its treatment, the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of mild to moderate OSA. Vivos Therapeutics also offers VivoScore, a comprehensive home sleep apnea test. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States...Where does VVOS stock trade?
Vivos Therapeutics Inc. (VVOS) is listed on NASDAQ.What sector and industry is VVOS in?
Vivos Therapeutics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Vivos Therapeutics Inc. go public?
Vivos Therapeutics Inc. (VVOS) completed its IPO in 2020.What are analysts saying about VVOS?
Vivos Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from Roth Capital: Buy with a $1000.00 price target on 2021-08-13. Recent price targets cluster around $1000.00.What companies are similar to VVOS?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare VVOS side-by-side with any of them on Quantisnow.How can I track VVOS on Quantisnow?
Quantisnow aggregates Vivos Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VVOS to receive live email and push alerts on every new disclosure.